Lansing Street Advisors’s AbbVie ABBV Stock Holding History

Lansing Street Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,526	Closed	-$562K	–	286
2023 Q1	$562K	Sell	3,526 -2,550	-42%	-$390K	0.35%	53
2022 Q4	$982K	Buy	6,076 +132	+2%	+$20.2K	0.67%	35
2022 Q3	$798K	Buy	5,944 +408	+7%	+$58.5K	0.62%	36
2022 Q2	$848K	Buy	5,536 +60	+1%	+$9.17K	0.66%	36
2022 Q1	$958K	Buy	+5,476	New	+$795K	0.61%	37

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Lansing Street Advisors's ABBV Position: Q2 2023 in Review

Lansing Street Advisors sold out of AbbVie (ABBV) in Q2 2023, closing a stake of 3,526 shares — an estimated $562K sold.

Lansing Street Advisors first reported a position in ABBV in Q1 2022 and held it in 5 quarters. The position peaked at $982K in Q4 2022. 3,076 funds tracked by Wall St. Rank hold ABBV as of Q2 2023.

Lansing Street Advisors reported no remaining AbbVie position as of Q2 2023 after selling out during the quarter.
Lansing Street Advisors sold 3,526 AbbVie shares in Q2 2023, an estimated $562K.
Lansing Street Advisors first reported a position in AbbVie in Q1 2022 and held it in 5 quarters.
Lansing Street Advisors's AbbVie position peaked at $982K in Q4 2022.
3,076 funds tracked by Wall St. Rank held AbbVie as of Q2 2023.

Based on Lansing Street Advisors's 13F filing for Q2 2023, filed 11 Aug 2023.